It looks like your are using Internet Explorer.

Unfortunately, Internet Explorer is an outdated browser and we do not currently support it fully. You are seeing a limited view of the meeting details below.

To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

DTx Evidence Generation: What can we learn from the Pharma and Medical Device Industries?

8th September @ 10:45AM EDT

The definition of Digital Therapeutics (DTx) is broad,  including many different solutions, making it hard to agree on the evidence generation standards. While DTx are very different from drugs and other medical devices, pharma and medtech companies have years of expertise in generating clinical and health economics evidence. In this meeting, we want to deep dive into what learnings the DTx industry can take from them and how should the standards evolve to capture the nuances of this new type of therapy. Join this meeting to have a peer-to-peer conversation about:

  • What can the DTx industry learn from pharma and medtech in building the evidence needed to get regulators, payers, and physicians to listen? 
  • In DTx, there is no one way, with different approaches that work for some products but not for others. This can also be true for drugs or other medical devices. How do pharma and medtech companies change their evidence generation approach depending on the product and the geographies? What learnings can we take to the DTx industry? 
  • It is not a secret that DTx and drugs are not the same, hence the standards need to evolve to adapt to these new digital therapies. What other non-traditional evidence is needed for DTx? What should DTx companies do differently from pharma and medtech when generating evidence for their products? 
  • Partnering with pharma and medtech companies to generate the evidence. Is this helpful for DTx companies or does it translate into more obstacles and longer trials?

Apply to Attend

Thank you! Your submission has been received.

An invite invite link has been sent to you if you do not already have a HealthXL account.
Oops! Something went wrong while submitting the form.

DTx Evidence Generation: What can we learn from the Pharma and Medical Device Industries?

Luis Fernandez-Luque
Chief Scientific Officer, Adhera Health
Myles Furnace
Board Advisor, Stress Point Health
Apply to Attend

DTx Evidence Generation: What can we learn from the Pharma and Medical Device Industries?

No items found.

Join this HealthXL Event today:

Participate in this Digital Health Sprint in order to:
- Deep dive into a topic over 2 focused sessions.
- Engage with a small group of 10 global thought-leaders throughout.
- This sprint is outcome-focused: HealthXL and participants create exclusive outputs.
- Grow your network with our break out sessions.


You actively participate in this discussion. Spaces are limited to 8 - 12 people, allowing you to focus on quality in-depth conversations.

Don't miss your opportunity to connect with senior leaders to shape the future of digital health. Because only if you are prepared now can you lead the future.

8th September @ 10:45AM EDT

The definition of Digital Therapeutics (DTx) is broad,  including many different solutions, making it hard to agree on the evidence generation standards. While DTx are very different from drugs and other medical devices, pharma and medtech companies have years of expertise in generating clinical and health economics evidence. In this meeting, we want to deep dive into what learnings the DTx industry can take from them and how should the standards evolve to capture the nuances of this new type of therapy. Join this meeting to have a peer-to-peer conversation about:

  • What can the DTx industry learn from pharma and medtech in building the evidence needed to get regulators, payers, and physicians to listen? 
  • In DTx, there is no one way, with different approaches that work for some products but not for others. This can also be true for drugs or other medical devices. How do pharma and medtech companies change their evidence generation approach depending on the product and the geographies? What learnings can we take to the DTx industry? 
  • It is not a secret that DTx and drugs are not the same, hence the standards need to evolve to adapt to these new digital therapies. What other non-traditional evidence is needed for DTx? What should DTx companies do differently from pharma and medtech when generating evidence for their products? 
  • Partnering with pharma and medtech companies to generate the evidence. Is this helpful for DTx companies or does it translate into more obstacles and longer trials?
Apply to AttendRegister to AttendApply to Attend

Participants

Participants

Luis Fernandez-Luque

Chief Scientific Officer, Adhera Health

Myles Furnace

Board Advisor, Stress Point Health

Adriano Garcez

Director, Evidence Generation & Outcomes Research, ZS Associates

Alyssa Dietz, Ph.D.

Senior Director, Precision Care Strategy, Twill

Anna-Maria Heidinger

Head of Digital Innovation Hub Europe, Daiichi Sankyo Europe GmbH

Emma Carr, PhD

Co-Founder and CSO, Amara Therapeutics

Ameya Phadke

Patient Non Pharma Solutions Leader - Chiesi Group

Maike Schmitz

Oncology Lead, RoX Health

Kasparas Aleknavičius

Healthcare Futurist, Kilo.Health

Angela Lu

Senior Consultant, Herspiegel Consulting

Maxime Champain

Lead, BDH External Innovation & Alliances, Search & Evaluation, Biogen

Dan Hoffman

Head - Digital Commercialization, Otsuka Precision Health

Philipp Unruh

Digital Product Manager, Bayer

Number of Participants


Up to 12
Date  
September 8, 2022
Community

DTx Evidence Generation: What can we learn from the Pharma and Medical Device Industries?

The definition of Digital Therapeutics (DTx) is broad,  including many different solutions, making it hard to agree on the evidence generation standards. While DTx are very different from drugs and other medical devices, pharma and medtech companies have years of expertise in generating clinical and health economics evidence. In this meeting, we want to deep dive into what learnings the DTx industry can take from them and how should the standards evolve to capture the nuances of this new type of therapy. Join this meeting to have a peer-to-peer conversation about:

  • What can the DTx industry learn from pharma and medtech in building the evidence needed to get regulators, payers, and physicians to listen? 
  • In DTx, there is no one way, with different approaches that work for some products but not for others. This can also be true for drugs or other medical devices. How do pharma and medtech companies change their evidence generation approach depending on the product and the geographies? What learnings can we take to the DTx industry? 
  • It is not a secret that DTx and drugs are not the same, hence the standards need to evolve to adapt to these new digital therapies. What other non-traditional evidence is needed for DTx? What should DTx companies do differently from pharma and medtech when generating evidence for their products? 
  • Partnering with pharma and medtech companies to generate the evidence. Is this helpful for DTx companies or does it translate into more obstacles and longer trials?
Participate in the Meeting

HealthXL Roundtables

HealthXL community meetings connect senior leaders from around the world.

Our virtual Roundtables are small, participant-led discussions where the HealthXL community discuss digital health challenges and offer solutions.

Participant-Led

HealthXL community members lead discussion on a defined topic among a maximum of 12 participants. There is no audience and no recordings, just an interactive space to reflect and share learnings.

Developed for a Busy Schedule

At 60-minutes long, roundtables are long enough for meaningful discussion among peers, but short enough to fit into busy schedules.

Check out our platform for the full HealthXL experience

Set up a free HealthXL platform account for a taste of what the community has to offer. Or talk to us about upgrading to a premium account:

  • Join any virtual and in-person events
  • Invite peers to meetings
  • Network
  • Gain full access to all articles and HealthXL reports
  • Get personalised recommendations
  • Join specialised communities in areas like DTx, AI, Clinical Trials Innovation and more
  • Full access to community insights and meeting takeaway reports

HealthXL Masterclasses

HealthXL community events give unparalleled access to digital health leaders from around the world.

Our virtual Masterclasses are 60-minute sessions where a recognised expert in their field provides an in-depth learning experience to a small audience of 8-12 members.

EXPERT-Led

HealthXL Masterclasses give you a chance to join a small group of peers and ask questions of recognised experts in a private, convenient setting.

Check out our platform for the full HealthXL experience

Set up a free HealthXL platform account for a taste of what the community has to offer. Or talk to us about upgrading to a premium account:

  • Join any virtual and in-person events
  • Invite peers to meetings
  • Network
  • Gain full access to all articles and HealthXL reports
  • Get personalised recommendations
  • Join specialised communities in areas like DTx, AI, Clinical Trials Innovation and more
  • Full access to community insights and meeting takeaway reports

HealthXL Webinars

HealthXL community events give unparalleled access to digital health experts from around the world.

Our webinars bring together panels of 3-4 global leaders from the HealthXL community to discuss core trends in digital health.

Expert Panel Discussion

Gain insights on the latest topics in digital health and ask questions of the expert panel via chat. Webinars run for 60 minutes and recordings are shared with all attendees afterwards.

Check out our platform for the full HealthXL experience

Set up a free HealthXL platform account for a taste of what the community has to offer. Or talk to us about upgrading to a premium account:

  • Join any virtual and in-person events
  • Invite peers to meetings
  • Network
  • Gain full access to all articles and HealthXL reports
  • Get personalised recommendations
  • Join specialised communities in areas like DTx, AI, Clinical Trials Innovation and more
  • Full access to community insights and meeting takeaway reports
Virtual Digital Health Meeting

Join from anywhere

No need for a high end laptop to display fancy 3D personas or interactive conference rooms: All you need is a working camera and an internet-ready device to join.

Apply to Attend now

The world of Digital Health in one Hub

Be ready for the future of Digital Health and join a community of passionate leaders, innovators and gamechangers. 

As a HealthXL member, you get access to a wealth of information, resources and connections. From daily curated news by our in-house expert team to industry reports each retailing at €2000 - you have the world of Digital Health right at your fingertips.

Our community is growing fast. Don’t miss out on your opportunity to lead the future.


Join the community here
Reports & Insights
Reports and insights shared by the DTx community
Curated
News
Daily DTx News Curated by our in-house experts
Lists & Dashboards
Interactive dashboards and downloadable organisation data

Your Digital Health Corner

All Posts
Commentary
February 16, 2024
Tess’ Top Takes from this Month’s Meetings in Digital Health: February 2024
Tess’ Top Takes from this Month’s Meetings in Digital Health: February 2024
Read More
Commentary
February 9, 2024
Is There a Space for Digital Health in the World of RNA Based Therapeutics?
Is There a Space for Digital Health in the World of RNA Based Therapeutics?
Read More
Commentary
February 2, 2024
AI in Clinical Trials: Navigating the Trial-and-Error Process
AI in Clinical Trials: Navigating the Trial-and-Error Process
Read More

DTx Evidence Generation: What can we learn from the Pharma and Medical Device Industries?

8th September @ 10:45AM EDT
Digital Therapeutics (DTx)

DTx Evidence Generation: What can we learn from the Pharma and Medical Device Industries?

8th September @ 10:45AM EDT
Digital Therapeutics (DTx)
Luis Fernandez-Luque
Chief Scientific Officer, Adhera Health
LinkedIn Profile
Myles Furnace
Board Advisor, Stress Point Health
LinkedIn Profile
Adriano Garcez
Director, Evidence Generation & Outcomes Research, ZS Associates
LinkedIn Profile
Alyssa Dietz, Ph.D.
Senior Director, Precision Care Strategy, Twill
LinkedIn Profile
Anna-Maria Heidinger
Head of Digital Innovation Hub Europe, Daiichi Sankyo Europe GmbH
LinkedIn Profile
Emma Carr, PhD
Co-Founder and CSO, Amara Therapeutics
LinkedIn Profile
Ameya Phadke
Patient Non Pharma Solutions Leader - Chiesi Group
LinkedIn Profile
Maike Schmitz
Oncology Lead, RoX Health
LinkedIn Profile
Kasparas Aleknavičius
Healthcare Futurist, Kilo.Health
LinkedIn Profile
Angela Lu
Senior Consultant, Herspiegel Consulting
LinkedIn Profile
Maxime Champain
Lead, BDH External Innovation & Alliances, Search & Evaluation, Biogen
LinkedIn Profile
Dan Hoffman
Head - Digital Commercialization, Otsuka Precision Health
LinkedIn Profile
Philipp Unruh
Digital Product Manager, Bayer
LinkedIn Profile

DTx Evidence Generation: What can we learn from the Pharma and Medical Device Industries?

The definition of Digital Therapeutics (DTx) is broad,  including many different solutions, making it hard to agree on the evidence generation standards. While DTx are very different from drugs and other medical devices, pharma and medtech companies have years of expertise in generating clinical and health economics evidence. In this meeting, we want to deep dive into what learnings the DTx industry can take from them and how should the standards evolve to capture the nuances of this new type of therapy. Join this meeting to have a peer-to-peer conversation about:

  • What can the DTx industry learn from pharma and medtech in building the evidence needed to get regulators, payers, and physicians to listen? 
  • In DTx, there is no one way, with different approaches that work for some products but not for others. This can also be true for drugs or other medical devices. How do pharma and medtech companies change their evidence generation approach depending on the product and the geographies? What learnings can we take to the DTx industry? 
  • It is not a secret that DTx and drugs are not the same, hence the standards need to evolve to adapt to these new digital therapies. What other non-traditional evidence is needed for DTx? What should DTx companies do differently from pharma and medtech when generating evidence for their products? 
  • Partnering with pharma and medtech companies to generate the evidence. Is this helpful for DTx companies or does it translate into more obstacles and longer trials?
When:
8th September @ 10:45AM EDT
Apply to attend
Registration Closed

Join this group of peers and get a feel of what it's like to belong to a community of digital health gamechangers.

All meetings are limited to 10 people to allow for honest discussions, so apply fast or become a HealthXL member and get priority access to all meetings, latest industry reports and and much more.

Frequently asked questions: 

What are HealthXL Virtual Meetings?

HealthXL Virtual Meetings are private group meetings limited to 10 people across different demographic and stakeholder groups. For 75 minutes, you take a deep dive into your chosen topic and explore it from different angles. Virtual Meetings are not webinars: There is no audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And through our Community Hub, you stay up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

How can I connect with other digital health leaders?

HealthXL brings together gamechangers of digital health to support honest discussions in small, private groups. In our Community Hub, for which you can register for free, you can follow a wide range of communities across telehealth, digital therapeutics, patient engagement and more. As a full HealthXL member, you also get access to curated news, the latest insights and an expert network to connect with. Join exclusive virtual meetings to exchange strategies, viewpoints and learnings with members from like-minded yet diverse stakeholder groups.

What are the benefits of being a HealthXL community member?

As member of HealthXL, you join a community of digital health thought leaders, innovators and game changers around the world. With your membership, you get access to hundreds of insights, reports and resources. You can browse a database with over 90k healthcare organizations and view their active strategic partnerships, commercial relationships, latest funding rounds and research. Through our in-house curated digital health newsfeed, you stay informed on the most impactful news and you can regularly meet with members to share learnings, discuss the latest developments and connect with peers of different demographical stakeholder groups. Contact us today to find out about pricing options.

Through focus groups, we bring together 6-10 thought leaders and industry stakeholders in a series of virtual meetings to collaborate around a defined topic. Each meeting gives the group the opportunity to examine, analyze and collaborate with one another around a digital health topic as well as produce a shareable result.